HC Wainwright Cuts Earnings Estimates for COMPASS Pathways

Key Points

• HC Wainwright has lowered its earnings estimates for COMPASS Pathways, expecting Q3 2025 earnings per share to be ($0.44), down from a previous estimate of ($0.38).
• Despite the downgrade, HC Wainwright maintains a "Buy" rating and a price objective of $40.00 for COMPASS Pathways stock.
• The company reported an earnings miss for Q2, with earnings per share of ($0.38), which was below the consensus estimate of ($0.37).

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Research analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for shares of COMPASS Pathways in a research report issued to clients and investors on Monday, August 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.44) for the quarter, down from their prior estimate of ($0.38). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways' Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.68) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.91) EPS, FY2027 earnings at ($0.96) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $1.00 EPS.

CMPS has been the subject of several other reports. Evercore ISI reissued an "in-line" rating and issued a $6.00 price target (down from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $12.00 price objective on shares of COMPASS Pathways in a report on Tuesday, May 27th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price objective on shares of COMPASS Pathways in a report on Friday, August 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, COMPASS Pathways has a consensus rating of "Moderate Buy" and a consensus price target of $16.29.

COMPASS Pathways Stock Down 2.7%

CMPS opened at $4.36 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82. The business has a 50 day simple moving average of $4.01 and a 200-day simple moving average of $3.82. The stock has a market capitalization of $418.30 million, a P/E ratio of -2.37 and a beta of 2.17. COMPASS Pathways has a 12 month low of $2.25 and a 12 month high of $8.54.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01).

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds have recently bought and sold shares of CMPS. Cerity Partners LLC purchased a new position in COMPASS Pathways during the first quarter worth $29,000. GAMMA Investing LLC grew its position in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after purchasing an additional 5,003 shares during the period. Ethos Financial Group LLC purchased a new stake in shares of COMPASS Pathways in the first quarter valued at $35,000. Flagship Harbor Advisors LLC grew its position in shares of COMPASS Pathways by 27.7% in the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after purchasing an additional 3,134 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of COMPASS Pathways in the first quarter valued at $41,000. Hedge funds and other institutional investors own 46.19% of the company's stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.